BridgeMD
New treatment option for Macular Degeneration
Official title A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
ClinicalTrials.gov ID: NCT07440225
What this study is testing
What is Tiespectus?
Tiespectus is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for macular degeneration.
Also referred to as EYE201, MK-8748.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 and older
You may be able to join if
- The main include but are not limited to the following:
- Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and...
- The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment The main
You likely can't join if
- include but are not limited to the following
- Has uncontrolled blood pressure at screening
- History of any prior macular laser photocoagulation in the study eye
- History of uveitis in either eye
- History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days...
- Has uncontrolled glaucoma in the study eye
See the full eligibility criteria
- The main include but are not limited to the following:
- Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and...
- The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment The main
- include but are not limited to the following
- Has uncontrolled blood pressure at screening
- History of any prior macular laser photocoagulation in the study eye
- History of uveitis in either eye
- History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study
- Has uncontrolled glaucoma in the study eye
- Active retinal disease other than the condition under investigation in the study eye
- Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye
The study team makes the final eligibility decision.
Where it's taking place
- Scottsdale, Arizona, United States
- Fayetteville, Arkansas, United States
- Springdale, Arkansas, United States
- Glendale, California, United States
- Modesto, California, United States
- Redlands, California, United States
- Sacramento, California, United States
- Altamonte Springs, Florida, United States
- Fort Lauderdale, Florida, United States
- Gainesville, Florida, United States
- Plantation, Florida, United States
- St. Petersburg, Florida, United States
- Tallahassee, Florida, United States
- Tampa, Florida, United States
- Wildwood, Florida, United States
- Oak Park, Illinois, United States
- Carmel, Indiana, United States
- Hagerstown, Maryland, United States
- Grand Rapids, Michigan, United States
- Madison, Mississippi, United States
+ 50 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Scottsdale, Arizona, United States; Fayetteville, Arkansas, United States; Springdale, Arkansas, United States; Glendale, California, United States; Modesto, California, United States; Redlands, California, United States and 64 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.